Neurocords

Company Overview

Snapshot

Founded in March 2018, Neurocords operates with 0 employees. The company was acquired by Orgenesis in March 2025, strengthening Orgenesis' regenerative medicine portfolio with spinal cord injury therapies.

Business overview

Neurocords specializes in developing regenerative therapies for spinal cord injuries. The company's core focus is a novel cellular therapy platform designed to restore function following such injuries. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology, Neurocords aims to address critical unmet needs in neural regeneration.

Strategic signal

In March 2025, Neurocords was acquired by Orgenesis Inc., a global biotech company. This strategic acquisition is significant as it integrates Neurocords' technology for regenerative medicine therapies into Orgenesis' decentralized cell processing approach, aiming to expand access to cost-effective treatments for spinal cord injuries. This move signals a strong validation of Neurocords' cellular therapy platform and its potential to accelerate the development of transformative therapies, indicating a positive growth trajectory under new ownership.

Company Intelligence Q&A

What is Neurocords' primary focus?

Neurocords is focused on developing regenerative therapies for spinal cord injuries, specifically through a novel cellular therapy platform aimed at restoring function.

When was Neurocords founded?

Neurocords was founded in March 2018.

What was a significant recent event for Neurocords?

In March 2025, Neurocords was acquired by Orgenesis Inc. This acquisition was aimed at strengthening Orgenesis' regenerative medicine portfolio with spinal cord injury therapies.

What is the strategic importance of the acquisition by Orgenesis?

The acquisition by Orgenesis Inc. in March 2025 is strategically important as it integrates Neurocords' technology with Orgenesis' decentralized cell processing approach, intending to expand access to cost-effective treatments and accelerate the development of therapies for spinal cord injuries.

In which sector does Neurocords primarily operate?

Neurocords primarily operates in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology.